# **Balaxi** Ventures Limited

July 22, 2020

To, Listing Department, National Stock Exchange of India Limited. Exchange Plaza, Plot No C/1, G Block, BKC, Bandra (E), Mumbai-400051

**Stock Code: BALAXI** 

Sub: Financial Results.

Dear Sir/Madam.

We wish to inform you that the Board of Directors at its meeting held today has interalia considered and approved the following matters;

- a. Unaudited Consolidated Financial Results of the Company for the Quarter and Three Months ended on June 30, 2020:
- b. Unaudited Standalone Financial Results of the Company for the Quarter and Three Months ended on June 30, 2020:

The board meeting was commenced on 13:00 Hrs and concluded by 13:17 Hrs. We are also arranging for the publication of the results in Newspapers & in the Website of the company.

Yours Faithfully,

For, Balaxi Ventures Limited,

Nidhin Jose

**Company Secretary** 

**Registered Office:** 

Plot No. 409, H.No. 8-2-293, Maps Towers, 3rd Floor, Phase-III, Road No. 81, Jubilee Hills, Hyderabad, Telangana, India - 500096.

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxiventures.in

Website: www.balaxiventures.in

# **Balaxi** Ventures Limited

				(Rs. in Lakhs)
Particulars		Quarter Ended		
	30.06.2020	31.03.2020	30.06.2019	31.03.2020
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
Income				
Revenue from operations	5,205.84	1,170.84	822.88	4,563.24
Other income	150.97	60.22	(3.92)	59.49
Total Income	5,356.81	1,231.05	818.96	4,622.73
Expenses				
Cost of materials consumed	3,924.42	853.38	597.43	3,285.14
Employee benefit expense	192.03	78.11	41.31	209.85
Finance cost	•	-	-	0-
Depreciation and amortisation expense	6.57	0.33	0.12	0.75
Other expenses	187.30	59.05	37.26	239.61
Total Expenses	4,310.33	990.88	676.11	3,735.36
Profit/(loss) before tax and other comprehensive income	1,046.49	240.18	142.84	887.37
Tax expenses	•			
Current tax	175.69	94.35	39.74	276.64
Deferred tax	0.50	0.02	-	0.34
Net Profit/(loss) for the period	870.30	145.80	103.10	610.40
Other comprehensive income				
A (i) Items that will not be reclassified to profit or loss in subsequent period				
Exchange differences on translation of foreign operations	(1.67)	2.55	-	2.55
(ii) Income tax relating to items that will not be reclassified to profit or loss				
B (i) Items that will be reclassified to profit or loss				
(ii) Income tax relating to items that will be reclassified to profit or loss				
Total comprehensive income for the year	868.63	148.35	103.10	612.94
Paid up equity share capital - Face value of Rs.10 each	1,000.00	1,000.00	304.00	1,000.00
Other Equity				
Earnings Per Share (EPS)				
(EPS for the quarter is not annualised)	200			
-Basic (Amount in Rs.)	8.70	1.46	3.39	8.12
-Diluted (Amount in Rs.)	8.70	1.46	3.39	8.12

#### Notes:

- 1. The Unaudited Consolidated Financial Results for the quarter ended June 30, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on July 22, 2020 and have been subjected to Limited Review by the Statutory Auditors of the Company. The Consolidated Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013.
- 2. The figures for the quarter ended March 31, 2020 are the balancing figures between audited figures in respect of full financial year and unaudited published year to date figures up to the third quarter of the respective financial year.
- 3. Previous period figures have been regrouped, re-arranged and re-classified wherever necessary to conform to current period's classification.
- 4. Balaxi Global DMCC, the wholly owned subsidiary of the company received capital contribution and completed other required legal formalities only on February 13, 2020. Therefore, figures for the guarter ended on 30.06.2019 are the standalone figures only.
- 5. During the quarter under review, the Company's wholly-owned subsidiary Balaxi Global DMCC, Dubai acquired Balaxi Healthcare Dominica SRL and Balaxi Healthcare Guatemala S.A. for an aggregate Enterprise Value of USD 2.2mn (INR 1,660.85 lakhs)
- 6. The Group is engaged in the Business of International Wholesale Trading and Distribution of Pharmaceuticals, Food Products and Builders' Hardware, with products sourced globally through contract manufacturing sites under Balaxi brands. Further, the Company's wholly-owned subsidiaries in Guatemala and Dominican Republic are also engaged in distribution of generic and branded generic pharmaceuticals through their local presence of warehouses and allied infrastructure, based on product registrations owned by them. Currently, all these operations fall under one reportable segment of International Wholesale Trading.

Hyderabad

Place: Hyderabad Date: July 22, 2020



For and on behalf of Board of Directors,

Ashish Maheshwari **Managing Director** 

**Registered Office:** 

Plot No.409, H.No. 8-2-293, Maps Towers, 3rd Floor, Phase-III, Road No. 81, Jubilee Hills, Hyderabad, Telangana, India - 500096.

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxiventures.in

Website: www.balaxiventures.in

DIN: 01575984

# **Balaxi** Ventures Limited

#### Unaudited Standalone Financial Results for the Quarter and Three Months Ended on June 30, 2020

(Rs. in Lakhs)

				(Rs. in Lakhs)	
Particulars	Quarter Ended			Year ended	
	30.06.2020 31.03.2020		30.06.2019	31.03.2020	
	(Unaudited)	(Audited)	(Unaudited)	(Audited)	
Income					
Revenue from operations	2,115.27	1,170.84	822.88	4,563.24	
Other income	146.76	60.22	(3.92)	59.49	
Total Income	2,262.03	1,231.05	818.96	4,622.73	
Expenses					
Cost of materials consumed	1,543.30	853.38	597.43	3,285.14	
Employee benefit expense	39.67	44.47	41.31	176.21	
Finance cost		-1		-	
Depreciation and amortisation expense	0.71	0.33	0.12	0.75	
Other expenses	49.33	53.51	37.26	234.07	
Total Expenses	1,633.01	951.70	676.11	3,696.18	
Profit/(loss) before tax and other comprehensive income	629.02	279.36	142.84	926.55	
Tax expenses					
Current tax	157.83	94.35	39.74	276.64	
Deferred tax	0.50	0.02	-	0.34	
Net Profit/(loss) for the period	470.69	184.98	103.10	649.58	
Other comprehensive income					
A (i) Items that will not be reclassified to profit or loss in subsequent period			-	-	
(ii) Income tax relating to items that will not be reclassified to profit or loss	C 5075	-	:-	-	
B (i) Items that will be reclassified to profit or loss			140	-	
(ii) Income tax relating to items that will be reclassified to profit or loss		-	-	-	
Total comprehensive income for the year	470.69	184.98	103.10	649.58	
Paid up equity share capital - Face value of Rs.10 each	1,000.00	1,000.00	304.00	1,000.00	
Other Equity					
Earnings Per Share (EPS)					
(EPS for the quarter is not annualised)					
-Basic (Amount in Rs.)	4.71	1.85	3.39	8.64	
-Diluted (Amount in Rs.)	4.71	1.85	3.39	8.64	

#### Notes:

- 1. The Unaudited Standalone Financial Results for the quarter ended June 30, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on July 22, 2020 and have been subjected to Limited Review by the Statutory Auditors of the Company. The Standalone Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013.
- 2. The figures for the quarter ended March 31, 2020 are the balancing figures between audited figures in respect of full financial year and unaudited published year to date figures up to the third quarter of the respective financial year.
- 3. Previous period figures have been regrouped, re-arranged and re-classified wherever necessary to conform to current period's classification.
- 4. The Company has decided to exercise the option permitted under Section 115BAA of the Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Act, 2019 w.e.f April 01,2020 onwards.
- 5. The Company is engaged in the Business of International Wholesale Trading and Distribution of Pharmaceuticals, Food Products and Builders' Hardware, with products sourced through contract manufacturing sites across India under Balaxi brands. Currently, all these operations fall under one reportable segment of International Wholesale Trading.
- 6. During the quarter under review, the Company has completed its initial investment of USD 1.50 Million (INR 1321.83 lakhs) in its wholly owned subsidiary Balaxi Global DMCC, Dubai

Hyderabac

Place: Hyderabad Date: July 22, 2020



For and on behalf of Board of Directors,

Ashish Maheshwari Managing Director DIN: 01575984

**Registered Office:** 

Plot No.409, H.No. 8-2-293, Maps Towers, 3rd Floor, Phase-III, Road No. 81, Jubilee Hills, Hyderabad, Telangana, India - 500096.

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxiventures.in

Website: www.balaxiventures.in



Tel. : (91-

: (91-40) 2332 6666, 2331 2554

2339 3967, 2332 1470

Fax : (91-40) 2339 2474 E-mail : pmurali.co@gmail.com

info@pmurali.com

Website: www.pmurali.com

Independent Auditor's Review Report on the Quarterly Unaudited Ind ASConsolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended

To The Board of Directors Balaxi ventures limited

We have reviewed the accompanying unaudited Ind ASConsolidated financial results of **BALAXI VENTURES LIMITED** (the "Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group"), for the quarter ended June 30, 2020 ("the Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34("Ind AS 34"), 'Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on "the Statement" based on our review

We conducted our review of "the Statement" in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether "the Statement" is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





: (91-40) 2332 6666, 2331 2554

2339 3967, 2332 1470

Fax

: (91-40) 2339 2474 E-mail: pmurali.co@gmail.com

info@pmurali.com

Website: www.pmurali.com

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

"The Statement" includes the Ind ASfinancial results of the following entities:

- 1. Balaxi Global DMCC, Dubai(wholly owned subsidiary) which included two of its wholly owned subsidiaries:
  - a) Balaxi Healthcare Dominica SRL, Dominican Republic
  - b)Balaxi Healthcare Guatemala S.A, Guatemala

Based on our review conducted and procedures performed as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The accompanying "Statement" includes unaudited interim Ind ASfinancial results and other unaudited financial information in respect of:

subsidiary, whose interim Ind ASfinancial results and other financial information reflect total revenues of Rs.3681.84 lakhs, total net profit after tax of Rs.563.30 and total comprehensive income of Rs.563.62 lakhs, for the quarter ended June 30,2020, as considered in "the Statement" whose interim Ind ASfinancial results and other financial information have not been reviewed by their auditors;

These unaudited interim Ind ASfinancial results and other unaudited financial information have been approved and furnished to us by the Management and our conclusion on "the Statement" in so far as it relates to the affairs of the subsidiary is based solely on such unaudited interim Ind ASfinancial results and other unaudited financial information



: (91-40) 2332 6666, 2331 2554

2339 3967, 2332 1470

Fax

: (91-40) 2339 2474

E-mail: pmurali.co@gmail.com

info@pmurali.com

Website: www.pmurali.com

Our conclusion on "the Statement" in respect of matters stated above is not modified with respect to our reliance on the Ind ASfinancial results certified by the Management.

For P. Murali& Co. Chartered Accountants

FRN: 007257S

P. MuraliMohanaRao

Partner

M.No. 023412

UDIN: 20023412AAAAFH1735

Place: Hyderabad Date: 22-07-2020.



: (91-40) 2332 6666, 2331 2554

2339 3967, 2332 1470

Fax

: (91-40) 2339 2474 : pmurali.co@gmail.com

info@pmurali.com

Website: www.pmurali.com

Independent Auditor's Review Report on the Quarterly Unaudited IndASStandalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors Balaxi ventures limited

We have reviewed the accompanying statement of unaudited Ind AS standalone financial results of **BALAXI VENTURES LIMITED** (the "Company") for the quarter ended June 30, 2020 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (,,Ind AS 34,')'Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on "the Statement" based on our review.

We conducted our review of "the Statement" in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether "the Statement" is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





: (91-40) 2332 6666, 2331 2554

2339 3967, 2332 1470

Fax

: (91-40) 2339 2474 : pmurali.co@gmail.com

info@pmurali.com

Website: www.pmurali.com

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying "Statement", prepared in accordance with the recognition and measurement principles laid down in the aforesaid "Ind AS 34" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it

For P. Murali& Co.

**Chartered Accountants** 

contains any material misstatement.

FRN: 007257S

P. MuraliMohanaRao

**Partner** 

M.No. 023412

UDIN: 20023412AAAAFG2746

Place: Hyderabad Date: 22-07-2020.